ATE360439T1 - Immunisierung gegen karzinome und ihre vorstufen - Google Patents

Immunisierung gegen karzinome und ihre vorstufen

Info

Publication number
ATE360439T1
ATE360439T1 AT01913586T AT01913586T ATE360439T1 AT E360439 T1 ATE360439 T1 AT E360439T1 AT 01913586 T AT01913586 T AT 01913586T AT 01913586 T AT01913586 T AT 01913586T AT E360439 T1 ATE360439 T1 AT E360439T1
Authority
AT
Austria
Prior art keywords
cells
peptide
mixture
peptides
lymphocytes
Prior art date
Application number
AT01913586T
Other languages
German (de)
English (en)
Inventor
Knebel Doeberitz Magnus Von
Michael Linnebacher
Wolfgang Rudy
Original Assignee
Knebel Doeberitz Magnus Von
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knebel Doeberitz Magnus Von filed Critical Knebel Doeberitz Magnus Von
Application granted granted Critical
Publication of ATE360439T1 publication Critical patent/ATE360439T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001148Regulators of development
    • A61K39/001149Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT01913586T 2000-02-10 2001-02-07 Immunisierung gegen karzinome und ihre vorstufen ATE360439T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10006033A DE10006033B4 (de) 2000-02-10 2000-02-10 Immunisierung eines Individuums gegen Carcinome und ihre Vorstufen

Publications (1)

Publication Number Publication Date
ATE360439T1 true ATE360439T1 (de) 2007-05-15

Family

ID=7630548

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01913586T ATE360439T1 (de) 2000-02-10 2001-02-07 Immunisierung gegen karzinome und ihre vorstufen

Country Status (9)

Country Link
US (3) US20030139334A1 (enExample)
EP (1) EP1253938B1 (enExample)
JP (1) JP4936626B2 (enExample)
AT (1) ATE360439T1 (enExample)
AU (1) AU2001239160A1 (enExample)
CA (1) CA2400007C (enExample)
DE (2) DE10006033B4 (enExample)
ES (1) ES2286108T3 (enExample)
WO (1) WO2001058477A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2412409T3 (es) 1997-12-22 2013-07-11 Euro-Celtique S.A. Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
RS50817B (sr) 2004-03-30 2010-08-31 Euro-Celtique S.A. Dozni oblik otporan na promene koji sadrži adsorbenti i sredstvo sa suprotnim dejstvom
US10279018B2 (en) * 2012-12-03 2019-05-07 Unity Biotechnology, Inc. Immunogenic compositions for inducing an immune response for elimination of senescent cells
CN103293308B (zh) * 2013-05-24 2014-11-26 尉军 一种检测肿瘤标志物p16抗原表位氨基酸序列及应用
CN111434674B (zh) * 2018-12-25 2024-02-09 上海细胞治疗集团有限公司 多肽组合物及其在癌症免疫治疗中的用途
CN111848732B (zh) * 2019-04-30 2024-03-12 上海细胞治疗集团有限公司 多肽组合物及疫苗

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889169A (en) * 1991-05-16 1999-03-30 Cold Spring Harbor Laboratory Cell cycle regulatory protein p16 gene
AU7015396A (en) * 1995-09-07 1997-03-27 Health Research Incorporated Cyclin e variants and use thereof
US5723313A (en) * 1995-09-27 1998-03-03 St. Jude Children's Research Hospital ARF-p19, a novel regulator of the mammalian cell cycle
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US6287569B1 (en) * 1997-04-10 2001-09-11 The Regents Of The University Of California Vaccines with enhanced intracellular processing
IL133912A0 (en) * 1997-07-10 2001-04-30 Ctl Immunotherapies Corp A method of inducing ctl response
AU1099699A (en) * 1997-10-15 1999-05-03 President And Fellows Of Harvard College Cell regulatory genes, encoded products, and uses related thereto
US6066651A (en) 1997-10-29 2000-05-23 Ortho-Mcneil Pharmaceutical, Inc. Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders
DE19829473C2 (de) * 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
CA2355901A1 (en) * 1998-12-17 2000-06-22 Cropdesign N.V. Plant cell cycle genes and uses thereof

Also Published As

Publication number Publication date
US20060210591A1 (en) 2006-09-21
CA2400007C (en) 2008-08-26
DE50112401D1 (de) 2007-06-06
US8946171B2 (en) 2015-02-03
US7569538B2 (en) 2009-08-04
EP1253938A2 (de) 2002-11-06
WO2001058477A3 (de) 2002-04-11
CA2400007A1 (en) 2001-08-16
ES2286108T3 (es) 2007-12-01
DE10006033A1 (de) 2001-08-23
US20110064770A1 (en) 2011-03-17
DE10006033B4 (de) 2005-11-10
JP4936626B2 (ja) 2012-05-23
AU2001239160A1 (en) 2001-08-20
EP1253938B1 (de) 2007-04-25
US20030139334A1 (en) 2003-07-24
JP2003522157A (ja) 2003-07-22
WO2001058477A2 (de) 2001-08-16

Similar Documents

Publication Publication Date Title
Woitas et al. CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes
Lattime et al. Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells
Kefalakes et al. Hepatitis D virus-specific CD8+ T cells have a memory-like phenotype associated with viral immune escape in patients with chronic hepatitis D virus infection
US20150250864A1 (en) Anti-cancer vaccines
Hartmann et al. Enhanced interleukin activity following asbestos inhalation
US8946171B2 (en) Immunization of an individual against carcinomas and the preliminary stages thereof
Körber et al. Hepatitis B vaccine non-responders show higher frequencies of CD24highCD38high regulatory B cells and lower levels of IL-10 expression compared to responders
Konnai et al. The influence of ovine MHC class II DRB1 alleles on immune response in bovine leukemia virus infection
US20090004742A1 (en) Selection of antigen-specific t cells
JP2005512517A (ja) 誘導性Hsp70由来のポリペプチドとこのポリペプチドを含有する医薬組成物
CN102353794B (zh) 筛选与鉴定幽门螺杆菌抗原表位肽的方法
CN102276697A (zh) 幽门螺杆菌抗原hla限制性免疫显性表位肽及应用
Castelli et al. Differential capacity of T cell priming in naive donors of promiscuous CD4+ T cell epitopes of HCV NS3 and Core proteins
US7108856B2 (en) CD4+ T-lymphocyte-specific Hepatitis C virus-epitopes
JP5133706B2 (ja) C型肝炎ウイルス由来ペプチド
Kita et al. A helper T‐cell antigen enhances generation of hepatitis C virus‐specific cytotoxic T lymphocytes in vitro
WO2017060283A1 (en) Specific immunodominant peptide epitopes for polyomavirus vaccine
Sundaram et al. Protective Efficacy of Multiepitope Human Leukocyte Antigen–A* 0201 Restricted Cytotoxic T-Lymphocyte Peptide Construct Against Challenge With Human T-Cell Lymphotropic Virus Type 1 Tax Recombinant Vaccinia Virus
CN106480003B (zh) 基于cd4+t细胞免疫的幽门螺杆菌优势抗原组合及筛选方法
Frasca et al. Antibody–Selected Mimics of Hepatitis C Virus Hypervariable Region 1 Activate Both Primary and Memory Th Lymphocytes
JP2009018990A (ja) C型肝炎ウイルス由来ペプチド
Cao et al. Vaccination with a multi‐epitopic recombinant allergen induces specific immune deviation via T‐cell anergy
Li et al. DNA vaccine expressing repeated carcinoembryonic antigen (CEA) 625–667 induces strong immunity in mice
CN102973950B (zh) Prame、wt1双价肿瘤dna疫苗
CN1785425B (zh) 牙鲆淋巴囊肿病的多肽疫苗的制备方法